BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16122842)

  • 1. [Treatment of essential thrombocythemia].
    Costello R; O'Callaghan T; Sébahoun G
    Rev Med Interne; 2005 Dec; 26(12):947-55. PubMed ID: 16122842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE
    Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anagrelide: what was new in 2004 and 2005?
    Petrides PE
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
    Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
    Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
    Gisslinger H; Gotic M; Holowiecki J; Penka M; Thiele J; Kvasnicka HM; Kralovics R; Petrides PE;
    Blood; 2013 Mar; 121(10):1720-8. PubMed ID: 23315161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
    Samuelson B; Chai-Adisaksopha C; Garcia D
    J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
    Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
    Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
    Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
    Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When and how to treat essential thrombocythemia.
    Barbui T; Finazzi G
    N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
    [No Abstract]   [Full Text] [Related]  

  • 14. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indications for lowering platelet numbers in essential thrombocythemia.
    Barbui T
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How should patients with essential thrombocythemia be treated?].
    Ikeda Y
    Rinsho Ketsueki; 2001 Jun; 42(6):447-51. PubMed ID: 11505520
    [No Abstract]   [Full Text] [Related]  

  • 17. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
    Barbui T
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
    Barbui T; Finazzi G
    Curr Hematol Rep; 2003 May; 2(3):248-56. PubMed ID: 12901347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of essential thrombocythemia].
    Alvarez-Larrán A; Cervantes F; Besses C
    Med Clin (Barc); 2013 Sep; 141(6):260-4. PubMed ID: 23490491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis and management of essential thrombocythemia.
    Beer PA; Green AR
    Hematology Am Soc Hematol Educ Program; 2009; ():621-8. PubMed ID: 20008247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.